Edgewise Therapeutics (EWTX) Projected to Release Quarterly Earnings on Thursday

Key Points

• Edgewise Therapeutics is expected to report Q3 2026 results before market open on November 5. Analysts project a loss of $0.532 per share and revenue of approximately $119.23 million; the company previously missed estimates with a Q2 loss of $0.53 per share.
• EWTX shares were up 2.4% at $40.49, with a market capitalization of about $4.4 billion and a 12-month trading range of $15.94 to $48.51.
• Wall Street’s consensus view is “Moderate Buy,” based on one Strong Buy, nine Buy, one Hold, and one Sell rating, with an average price target of $51.33. Insiders have sold roughly $1.68 million of stock over the past 90 days, primarily to cover tax obligations tied to equity awards.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.5320) per share and revenue of $119.23 million for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 9:30 AM ET.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.06). On average, analysts expect Edgewise Therapeutics to post ($2.09) EPS for the current fiscal year and ($1.78) EPS for the next fiscal year.

Edgewise Therapeutics Trading Up 2.4%

EWTX stock opened at $40.49 on Thursday. Edgewise Therapeutics has a 12 month low of $15.94 and a 12 month high of $48.51. The stock has a market capitalization of $4.40 billion, a P/E ratio of -21.89 and a beta of 0.35. The firm has a 50-day moving average price of $41.58 and a 200-day moving average price of $36.09.

Insider Buying and Selling at Edgewise Therapeutics

In other news, insider Alan J. Russell sold 5,901 shares of Edgewise Therapeutics stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $43.73, for a total value of $258,050.73. Following the completion of the transaction, the insider owned 31,466 shares of the company's stock, valued at $1,376,008.18. The trade was a 15.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Kevin Koch sold 17,971 shares of Edgewise Therapeutics stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $43.68, for a total value of $784,973.28. Following the completion of the transaction, the chief executive officer directly owned 52,488 shares of the company's stock, valued at approximately $2,292,675.84. This represents a 25.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 38,329 shares of company stock valued at $1,675,529. Insiders own 21.30% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on EWTX shares. Guggenheim boosted their price objective on Edgewise Therapeutics from $41.00 to $51.00 and gave the company a "buy" rating in a research note on Monday, July 6th. HC Wainwright restated a "buy" rating on shares of Edgewise Therapeutics in a research note on Wednesday, October 14th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Edgewise Therapeutics in a report on Thursday, October 15th. JPMorgan Chase & Co. increased their price target on shares of Edgewise Therapeutics from $53.00 to $60.00 and gave the company an "overweight" rating in a research report on Thursday, August 20th. Finally, William Blair initiated coverage on shares of Edgewise Therapeutics in a report on Friday, October 16th. They set an "outperform" rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $51.33.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule therapies for severe muscle disorders. The company's research programs target the biology of skeletal and cardiac muscle, with the goal of addressing diseases for which treatment options remain limited.

Edgewise's lead product candidate is sevasemten (formerly EDG-5506), an oral therapy designed to reduce contraction-induced muscle damage associated with dystrophinopathies, including Duchenne and Becker muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.